Abstract Objective To investigate the incidence of systemic reactions (SR) to subcutaneous immunotherapy (SCIT) for bronchial asthma and/or allergic rhinitis in children and their risk factors. Methods A retrospective analysis was performed on 198 children with bronchial and/or allergic rhinitis. According to the presence or absence of SR and local reactions (LR) during SCIT, the patients were divided into two groups:SR (with SR and LR, n=31) and control (without SR or LR, n=142). A multivariate logistic regression analysis was used to determine the risk factors associated with SR. Results Among the 198 patients who received 8 157 injections of SCIT, 25 (12.6%) experienced SR (31 times, 0.38%), including grade I SR (18 times, 58%), grade II SR (10 times, 32%), grade III SR (3 times, 10%), and no grade IV SR. The multivariate logistic regression analysis showed that multiple sensitization with both food and inhaled allergens, specific IgE to dust mites (grade 6), total IgE (grade 6), and a history of LR were independent risk factors for SR (P < 0.05). Conclusions SCIT is a safe treatment for bronchial asthma and/or allergic rhinitis in children, with a low incidence of SR. Children with multiple sensitization with both food and inhaled allergens, a hypersensitive state (specific IgE to dust mites, grade 6; total IgE, grade 6), and a history of LR have an increased risk of SR to SCIT.
LIAO Wang,CHEN Liang,BAI Jun. Systemic reactions to subcutaneous immunotherapy for bronchial asthma and/or allergic rhinitis in children and their risk factors[J]. CJCP, 2020, 22(11): 1204-1208.
LIAO Wang,CHEN Liang,BAI Jun. Systemic reactions to subcutaneous immunotherapy for bronchial asthma and/or allergic rhinitis in children and their risk factors[J]. CJCP, 2020, 22(11): 1204-1208.
Tang RB. House dust mite-specific immunotherapy alters the natural course of atopic march[J]. J Chin Med Assoc, 2020, 83(2):109-112.
[3]
Jutel M, Brüggenjürgen B, Richter H, et al. Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma[J]. Allergy, 2020, 75(8):2046-2054.
[4]
Lim CE, Sison CP, Ponda P. Comparison of pediatric and adult systemic reactions to subcutaneous immunotherapy[J]. J Allergy Clin Immunol Pract, 2017, 5(5):1241-1247.e2.
Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy[J]. Allergy, 2006, 61(Suppl 82):1-20.
[8]
Tophof MA, Hermanns A, Adelt T, et al. Side effects during subcutaneous immunotherapy in children with allergic diseases[J]. Pediatr Allergy Immunol, 2018, 29(3):267-274.
Liu JL, Ning WX, Li SX, et al. The safety profile of subcutaneous allergen immunotherapy in children with asthma in Hangzhou, East China[J]. Allergol Immunopathol (Madr), 2017, 45(6):541-548.
[11]
Bernstein DI, Epstein TEG. Safety of allergen immunotherapy in North America from 2008-2017:lessons learned from the ACAAI/AAAAI national surveillance study of adverse reactions to allergen immunotherapy[J]. Allergy Asthma Proc, 2020, 41(2):108-111.
[12]
van de Veen W, Wirz OF, Globinska A, et al. Novel mechanisms in immune tolerance to allergens during natural allergen exposure and allergen-specific immunotherapy[J]. Curr Opin Immunol, 2017, 48:74-81.
Dong X, Huang N, Li W, et al. Systemic reactions to dust mite subcutaneous immunotherapy:a 3-year follow-up study[J]. Allergy Asthma Immunol Res, 2016, 8(5):421-427.
[15]
Nacaroglu HT, Erdem SB, Sumer O, et al. Local and systemic reactions to subcutaneous allergen immunotherapy:ten years' experience in a pediatric clinic[J]. Ann Allergy Asthma Immunol, 2016, 116(4):349-353.
[16]
Sani S, Gupta R, Fonacier L, et al. Risk stratification of systemic reactions to subcutaneous immunotherapy:a retrospective study[J]. Allergy Asthma Proc, 2019, 40(5):338-342.
[17]
Wahn U, Matricardi PM, Bieber T, et al. Food allergy in EAACI journals (2016)[J]. Pediatr Allergy Immunol, 2017, 28(8):825-830.
[18]
Kartal O, Gulec M, Caliskaner Z, et al. Safety of subcutaneous immunotherapy with inhalant allergen extracts:a single-center 30-year experience from Turkey[J]. Immunopharmacol Immunotoxicol, 2015, 37(3):280-286.
